Arena Pharma (ARNA) Sees Early Pressure Following Recent Buying Frenzy
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals (Nasdaq: ARNA) is seeing a rare down day which, actually might not last too much longer based on how the stock is moving.
Option implied volatility is up 2.6 points from Wednesday's closed to 178 percent.
Shares are down about 3 percent on the session.
Traders have been buying Arena ahead of its FDA PDUFA meeting date for lorcaserin, its proposed obesity-fighting drug. Shares have more than doubled since a positive panel outcome for the drug on May 10th.
Shares have ended lower just five of the last 17 sessions.
Option implied volatility is up 2.6 points from Wednesday's closed to 178 percent.
Shares are down about 3 percent on the session.
Traders have been buying Arena ahead of its FDA PDUFA meeting date for lorcaserin, its proposed obesity-fighting drug. Shares have more than doubled since a positive panel outcome for the drug on May 10th.
Shares have ended lower just five of the last 17 sessions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Saudi Arabia cut the price of its main crude grade for customers in Asia in August - Bloomberg
- Shift4 Payments (FOUR) call put ratio 13.4 calls to 1 put with a focus on July 60 calls
- Dataram (DRAM) call put ratio 1.4 calls to 1 put into SK Hynix plans to raise up to $29B
Create E-mail Alert Related Categories
Insiders' Blog, Options, Trader TalkRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
